 Galapagos NV NASDAQ: GLPG reports topline results from three studies evaluating GLPG3970, a SIK inhibitor, in psoriasis, ulcerative colitis UC, and rheumatoid arthritis RA. 26-patient CALOSOMA psoriasis trial. 